LAS VEGAS, Nov. 2 /PRNewswire-FirstCall/ -- VMT Scientific Inc.
(OTC: VMTF) announces its globally patented breakthrough technology that may
make the need for Peripheral Vascular Disease (PVD) and Diabetic associated
amputations obsolete. Its technology, the VasCir(TM) system is designed to
re-establish microvascularization and Tissue Histogenesis.
Engineering and the Science: VMT Scientific Inc. has patented a unique
design of sophisticated negative pressure technology that leads to the first
controlled and repeatable method of soft tissue histogenesis. The technology
also has identified several additional unique medical applications and is
protected both domestically and internationally by patents. The patented
methodology and technology is focused on the values perceived in the areas of
neurology, vascular disease, pediatric medicine and reconstructive/aesthetic
VMT Scientific Inc. is focused to mature this technology through
additional objective evidence with clinical trials. The clinical data will be
used to file for clearance with the FDA for the therapeutical treatment of
"Diabetic Neuropathy and PVD." Upon clearance, VMT Scientific Inc. will make
available license rights of the VasCir(TM) to manufacturers and distribution
The Technological FACTS are:
* Tissue histogenesis is well known and documented.
* The independent production of new tissue is produced through proper
stimulation and the benefits have been shown to last for years.
* Damaged tissues respond with accentuated healing capabilities.
* The VasCir(TM) system has demonstrated its ability to "non-invasively"
control blood flow with increases up to 300%.
* DYNAMICALY controlled increases in blood flow have a dramatic immune
* DYNAMICALY controlled increases in blood flow to areas previously
ischemic facilitates the regeneration of neurological tissues.
Please visit VMT Scientific, Inc.'s Web site for more information:
This Press Release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. You should not place undue reliance on these forward-looking
statements. These statements involve risks and uncertainties that could cause
actual results to differ materially from those suggested in the forward-
looking statements, particularly those risks and uncertainties inherent in the
process of developing, manufacturing and distributing medical products and
Clinical trials. Factors that may cause such a difference include risks
related to VMT Scientific Inc.'s limited operating history, risks associated
with completing development and obtaining FDA medical approvals, successful
patent protection and prosecution, successful sale of licensed technology
nationally or internationally. VMT Scientific technology will not meet with
market acceptance, the risk of future warranty and product liability claims,
the uncertainty of VMT Scientific Inc.'s future access to capital to sustain
operations, achieve profitability or continue as a going concern, the failure
by VMT Scientific Inc.'s to secure and maintain relationships with suppliers,
manufacturers and other third parties, reliance on key employees, and
dependence on intellectual property. World events, national economy and/or
other conditions and circumstances beyond our control. Further information on
the factors and risks that could affect VMT Scientific Inc.'s business,
financial condition and results of operations. These forward-looking
statements are based on information and management's expectations as of the
date hereof. Future results may differ materially from our current
expectations. VMT Scientific Inc.'s disclaims any intent or obligation to
update whose forward-looking statements.
"Saving feet and limbs is what it's all about"
Says VMT Scientific Inc.
SOURCE VMT Scientific, Inc.